Last reviewed · How we verify

loteprednol etabonate/tobramycin opthalmic suspension

Bausch & Lomb Incorporated · FDA-approved active Small molecule

loteprednol etabonate/tobramycin opthalmic suspension is a Corticosteroid/Aminoglycoside antibiotic combination Small molecule drug developed by Bausch & Lomb Incorporated. It is currently FDA-approved for Steroid-responsive inflammatory ocular conditions with bacterial infection or risk of bacterial infection, Post-operative ocular inflammation and infection prophylaxis. Also known as: Zylet.

Loteprednol etabonate reduces ocular inflammation via glucocorticoid receptor activation, while tobramycin provides broad-spectrum bacterial coverage by inhibiting bacterial protein synthesis.

Loteprednol etabonate reduces ocular inflammation via glucocorticoid receptor activation, while tobramycin provides broad-spectrum bacterial coverage by inhibiting bacterial protein synthesis. Used for Steroid-responsive inflammatory ocular conditions with bacterial infection or risk of bacterial infection, Post-operative ocular inflammation and infection prophylaxis.

At a glance

Generic nameloteprednol etabonate/tobramycin opthalmic suspension
Also known asZylet
SponsorBausch & Lomb Incorporated
Drug classCorticosteroid/Aminoglycoside antibiotic combination
TargetGlucocorticoid receptor (loteprednol); bacterial ribosome 30S subunit (tobramycin)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

Loteprednol etabonate is a corticosteroid that suppresses inflammatory mediators and immune responses in the eye. Tobramycin is an aminoglycoside antibiotic that binds to bacterial ribosomes and inhibits protein synthesis, providing coverage against gram-negative and gram-positive bacteria. The combination addresses both inflammatory and infectious components of ocular disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about loteprednol etabonate/tobramycin opthalmic suspension

What is loteprednol etabonate/tobramycin opthalmic suspension?

loteprednol etabonate/tobramycin opthalmic suspension is a Corticosteroid/Aminoglycoside antibiotic combination drug developed by Bausch & Lomb Incorporated, indicated for Steroid-responsive inflammatory ocular conditions with bacterial infection or risk of bacterial infection, Post-operative ocular inflammation and infection prophylaxis.

How does loteprednol etabonate/tobramycin opthalmic suspension work?

Loteprednol etabonate reduces ocular inflammation via glucocorticoid receptor activation, while tobramycin provides broad-spectrum bacterial coverage by inhibiting bacterial protein synthesis.

What is loteprednol etabonate/tobramycin opthalmic suspension used for?

loteprednol etabonate/tobramycin opthalmic suspension is indicated for Steroid-responsive inflammatory ocular conditions with bacterial infection or risk of bacterial infection, Post-operative ocular inflammation and infection prophylaxis.

Who makes loteprednol etabonate/tobramycin opthalmic suspension?

loteprednol etabonate/tobramycin opthalmic suspension is developed and marketed by Bausch & Lomb Incorporated (see full Bausch & Lomb Incorporated pipeline at /company/bausch-lomb-incorporated).

Is loteprednol etabonate/tobramycin opthalmic suspension also known as anything else?

loteprednol etabonate/tobramycin opthalmic suspension is also known as Zylet.

What drug class is loteprednol etabonate/tobramycin opthalmic suspension in?

loteprednol etabonate/tobramycin opthalmic suspension belongs to the Corticosteroid/Aminoglycoside antibiotic combination class. See all Corticosteroid/Aminoglycoside antibiotic combination drugs at /class/corticosteroid-aminoglycoside-antibiotic-combination.

What development phase is loteprednol etabonate/tobramycin opthalmic suspension in?

loteprednol etabonate/tobramycin opthalmic suspension is FDA-approved (marketed).

What are the side effects of loteprednol etabonate/tobramycin opthalmic suspension?

Common side effects of loteprednol etabonate/tobramycin opthalmic suspension include Ocular irritation or discomfort, Conjunctival erythema, Transient blurred vision, Allergic reaction.

What does loteprednol etabonate/tobramycin opthalmic suspension target?

loteprednol etabonate/tobramycin opthalmic suspension targets Glucocorticoid receptor (loteprednol); bacterial ribosome 30S subunit (tobramycin) and is a Corticosteroid/Aminoglycoside antibiotic combination.

Related